Identification of molecular biomarkers of untreated follicular lymphoma treated by GB therapy.

Clinical and molecular background associated with obinituzumab response in follicular lymphoma

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1060200019

Enrollment

150

Registered

2020-10-09

Start date

2021-01-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Follicular lymphoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Histologically proven CD20 positive follicular lymphoma (Grade 1, 2, 3A). 2) Age 70-year-old or more. 3) Treated by GB therapy as an initial therapy. 4) Written informed consent

Exclusion criteria

Exclusion criteria: Patients who refuse to participate in the study

Design outcomes

Primary

Measure	Time frame
The rate of POD24	—

Secondary

Measure	Time frame
1) 2-year PFS (Relapse free survival) 2) Overall response rate (ORR) at the end of GB therapy 3) 3-year OS (Overall survival) 4) 3-year OS (Overall survival) of the patients with POD24	—

Contacts

Public ContactDaisuke Ennishi

Center for Comprehensive Genomic Medicine, Okayama University Hospital

daisukeennishi@okayama-u.ac.jp+81-86-235-7414

Outcome results